Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion

Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial.

(2017) A. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Bisphosphonate Use and the Risk of Adverse Jaw Outcomes

(2014) Vassiliki M. Cartsos et al.   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

Abstract P6-14-01: Effect of Denosumab Versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase:

(2011) A Stopeck et al.   CANCER RESEARCH

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

(2011) Tim Van den Wyngaert et al.   SUPPORTIVE CARE IN CANCER

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

(2010) H. Eidtmann et al.   ANNALS OF ONCOLOGY

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST.:

(2010) R. Coleman et al.   CANCER RESEARCH

Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease

(2010) H.L. Neville-Webbe et al.   EUROPEAN JOURNAL OF CANCER

Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis

(2010) Antonis Valachis et al.   GYNECOLOGIC ONCOLOGY

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

(2010) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

(2010) Daniel Schramek et al.   NATURE

Zoledronic acid for breast cancer therapy-induced bone loss

(2010) Eitan Amir et al.   Nature Reviews Clinical Oncology

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland

(2010) M. Beleut et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Emerging treatments for postmenopausal osteoporosis – focus on denosumab

(2010) Piet Geusens   Clinical Interventions in Aging

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

(2009) Adam M. Brufsky et al.   Clinical Breast Cancer

Role of denosumab in breast cancer

(2009) Rupert Bartsch et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis

(2009) A. D. Anastasilakis et al.   HORMONE AND METABOLIC RESEARCH

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

(2009) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

(2008) Georgiana K. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

(2008) Stephanie L. Hines et al.   JOURNAL OF CLINICAL ONCOLOGY